NASA RealWorld-InWorld Engineering Design Challenge

One Year Post-Launch of Argenx's Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights

Retrieved on: 
Friday, February 24, 2023
Neurology, PDUFA, Genentech, UCB, Research, Neonatal Fc receptor, NMOSD, Patient, NASA RealWorld-InWorld Engineering Design Challenge, Inebilizumab, Market, Janssen, GMG, Hatred, Launch, Nursing, Pharmaceutical industry, Efgartigimod alfa, Ravulizumab, EU

EXTON, Pa., Feb. 24, 2023 /PRNewswire/ -- Argenx's launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic approved for generalized myasthenia gravis (gMG) and the first neonatal Fc receptor (FcRn) blocker, Vyvgart's novel and targeted mechanism of action has resonated with HCPs. Indeed, neurologists and neuromuscular specialists surveyed by Spherix Global Insights consider Vyvgart to address a substantial unmet in the treatment of this chronic, rare autoimmune condition.

Key Points: 
  • Indeed, neurologists and neuromuscular specialists surveyed by Spherix Global Insights consider Vyvgart to address a substantial unmet in the treatment of this chronic, rare autoimmune condition.
  • Despite these positive perceptions of argenx's brand, surveyed respondents (n=69) remain less confident in Vyvgart's dosing profile.
  • Interestingly, even with increased experience among neurologists, half continue to report uncertainty as to when to re-dose patients after the first Vyvgart treatment cycle.
  • Indeed, when probed unaided on Vyvgart's biggest disadvantages, two in five offered its dosing profile as a leading disadvantage.

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

Retrieved on: 
Friday, February 17, 2023
Launch, NASA RealWorld-InWorld Engineering Design Challenge, Neurology, DMTS, Patient, TG, Merck Serono, Therapy, RealTime, Siponimod, Sanofi, FDA, Multiple sclerosis, BTK, MS, Fine chemical, Online shopping, Pharmaceutical industry, Genentech, Novartis, Biogen, Ublituximab

EXTON, Pa., Feb. 17, 2023 /PRNewswire/ -- According to Biogen's earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a row. The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift in prescribing patterns.

Key Points: 
  • The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift in prescribing patterns.
  • As part of its' quarterly market tracking RealTime Dynamix™ service, Spherix Global Insights probed U.S. neurologists on satisfaction with Biogen's and Novartis' MS DMTs, as well as perceptions of both companies' MS portfolios.
  • Additionally, outside of branded DMTs, the MS market could see its first-ever biosimilar, with the expected launch of Sandoz/Polpharma Biologics' biosimilar natalizumab.
  • Since 2016, Spherix Global Insights has tracked the MS market and will continue coverage of this highly dynamic space.

Inworld AI: 99% of gamers are excited by the potential of smart NPCs powered by advanced artificial intelligence

Retrieved on: 
Wednesday, February 15, 2023
Life, Non-player character, Animation, NPC, Animal Crossing, Massively multiplayer online role-playing game, Humour, RPG, Entrepreneurship, Face, GTA, Human, Sale, Behavior, SAN, Immersion, Video, Roguelike, NASA RealWorld-InWorld Engineering Design Challenge, AI, Personality, Walking, Ageing, Video game, Toy, Male, Female

SAN FRANCISCO, Feb. 15, 2023 /PRNewswire/ -- Inworld AI, a developer platform for advanced NPC behavior and dialogue, today released the findings of its new report 'Gamer Attitudes to NPCs.' In the first study of its kind, the report surveyed over 1,000 gamers in the US aged 16-50 and found high levels of excitement about the potential of AI in video games. Specifically, there was an overwhelming consensus that recent advancements in AI could change the face of gaming and usher in a new era of immersion and interaction with NPCs (non-playable characters) with individual personalities and the ability to converse unscripted voice-to-voice with the help of ChatGPT-like language models and multimodal behavior and perception systems.

Key Points: 
  • Meaningful interactions with NPCs were heavily sought after, with only 9% of players dismissing or avoiding NPCs during gameplay altogether.
  • A large minority (40%) even admitted to talking to as many NPCs as possible to unlock more story content.
  • Equally, 91% interacted with NPCs on some level and 78% said they would spend more time playing a game with 'intelligent' NPCs.
  • With advanced AI NPCs, there's an opportunity for games to give players more of the immersive and realistic interactions with NPCs that gamers want."

Inworld.AI: 99% of gamers are excited by the potential of smart NPCs powered by advanced artificial intelligence

Retrieved on: 
Wednesday, February 15, 2023
Life, Non-player character, Animation, NPC, Animal Crossing, Massively multiplayer online role-playing game, Humour, RPG, Entrepreneurship, Face, GTA, Human, Sale, Behavior, SAN, Immersion, Video, Roguelike, NASA RealWorld-InWorld Engineering Design Challenge, AI, Personality, Walking, Ageing, Video game, Toy, Male, Female

SAN FRANCISCO, Feb. 15, 2023 /PRNewswire/ -- Inworld AI, a developer platform for advanced NPC behavior and dialogue, today released the findings of its new report 'Gamer Attitudes to NPCs.' In the first study of its kind, the report surveyed over 1,000 gamers in the US aged 16-50 and found high levels of excitement about the potential of AI in video games. Specifically, there was an overwhelming consensus that recent advancements in AI could change the face of gaming and usher in a new era of immersion and interaction with NPCs (non-playable characters) with individual personalities and the ability to converse unscripted voice-to-voice with the help of ChatGPT-like language models and multimodal behavior and perception systems.

Key Points: 
  • Meaningful interactions with NPCs were heavily sought after, with only 9% of players dismissing or avoiding NPCs during gameplay altogether.
  • A large minority (40%) even admitted to talking to as many NPCs as possible to unlock more story content.
  • Equally, 91% interacted with NPCs on some level and 78% said they would spend more time playing a game with 'intelligent' NPCs.
  • With advanced AI NPCs, there's an opportunity for games to give players more of the immersive and realistic interactions with NPCs that gamers want."

Switching Patterns Among Diabetic Macular Edema: Regeneron's Eylea Withstands the Evolving DME Switch Landscape

Retrieved on: 
Monday, February 13, 2023
Ranibizumab, Physician, NASA RealWorld-InWorld Engineering Design Challenge, Traction, Genentech, Ophthalmology, DME, Faricimab, Safety, Patient, Diabetic retinopathy, Regeneron Pharmaceuticals, Pharmaceutical industry

EXTON, Pa., Feb. 13, 2023 /PRNewswire/ -- The patient switch territory is evolving as more agents become available. Spherix's RealWorld Dynamix™ report allows for an inside look into real patient data, painting a more colorful picture of the switch patient demographic and highlighting the specific reasoning behind these complex decisions.   

Key Points: 
  • With the DME treatment landscape evolving, ophthalmologists have the opportunity to explore more novel approaches in hopes of easing treatment burden.
  • EXTON, Pa., Feb. 13, 2023 /PRNewswire/ -- The patient switch territory is evolving as more agents become available.
  • However, there is little hesitation amongst ophthalmologists when switching a patient to a new DME therapy.
  • The future of switching demonstrates a more diverse landscape, with Vabysmo expected to gain traction while Lucentis continues to recede.

Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights

Retrieved on: 
Thursday, February 9, 2023
Ulcerative colitis, Physician, NASA RealWorld-InWorld Engineering Design Challenge, Pfizer, Patient, Pulse, JAK, RealTime, UC, FDA, Growth, AbbVie, S1P, Pharmaceutical industry, Ozanimod

EXTON, Pa., Feb. 9, 2023 /PRNewswire/ -- Analysis from Spherix Global Insights quarterly market tracker, RealTime Dynamix™: Ulcerative Colitis, reveals that at twenty (20) months after the FDA approved Zeposia for use in Ulcerative Colitis (UC), stated physician use of the therapy remains low. A retrospective analysis across Spherix services suggests the drug has yet to cement a clear position which physicians commonly view as appropriate for the management of their UC patients.

Key Points: 
  • Zeposia is the only oral therapy indicated for the treatment of UC, which does not include a black box in its label.
  • That distinction gives it an advantage over the JAK class of medications, including Pfizer's Xeljanz (tofacitinib) and AbbVie's more recently launched Rinvoq (upadacitinib).
  • It is an advantage that affords Zeposia the opportunity to be prescribed in a first-line position ahead of biologics following an inadequate response to conventional systemic agents.
  • Despite this edge, physicians report prescribing Zeposia most often as a second or later line therapy, with its greatest proportion in third-line.

THINK Learning Studio Looks Into the Future with "Foresight Lab" Launch

Retrieved on: 
Thursday, February 9, 2023
Deep Dive Dubai, Learning, NASA RealWorld-InWorld Engineering Design Challenge, THINK, Deep Learning Studio, Foresight, Sustainability, Student, International, Education, Thought, Advanced Training, Creative industries, Management

NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Academic innovators at THINK Learning Studio announced today the launch of a new program in their commitment to the future of education: the "Foresight Lab." This new initiative will focus on empowering educators, entrepreneurs and multidisciplinary professionals to shape the future purposefully and creatively.

Key Points: 
  • NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Academic innovators at THINK Learning Studio announced today the launch of a new program in their commitment to the future of education: the "Foresight Lab."
  • THINK Learning Studio is an innovative consultancy and training platform shaping modern education around the world.
  • "We are so excited to officially launch our Foresight Lab and continue expanding THINK Learning Studio's offerings," said Christian Long, Chief Growth Officer at THINK Learning Studio.
  • "Future preparedness is seldom the focus in the world of academia, and rarely is it done in a creative and transformative way," said Russell Cailey, Managing Director at THINK Learning Studio.

U.S. Nephrologists Report Mixed Reactions to the Approval of GSK's Jesduvroq® (daprodustat) for the Treatment of Anemia in Dialysis Patients, According to Spherix Global Insights

Retrieved on: 
Thursday, February 9, 2023
Coronary thrombosis, GSK, Health, Physician, NASA RealWorld-InWorld Engineering Design Challenge, Australian Food Safety Information Council, Black box, Daprodustat, Anemia, Complete Response Letter, CKD, Dialysis, Patient, Frustration, Pulse, Thrombosis, Myocardial infarction, Black, Risk, Hypertension, Attitude, Death, Stroke, FDA, Chronic kidney disease, ESA, Nephrology, US Foods, Cardiovascular disease, Cancer, Pharmaceutical industry, Dietary supplement, Medical device, Akebia

EXTON, Pa., Feb. 9, 2023 /PRNewswire/ -- Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists' perceptions and opinions of new therapies and management protocols. This heritage of renal market insight includes measuring nephrologists' evolving use of treatment options and their enthusiasm and projections for assets in the pipeline – most notably the oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class.

Key Points: 
  • EXTON, Pa., Feb. 9, 2023 /PRNewswire/ -- Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists' perceptions and opinions of new therapies and management protocols.
  • [1]
    GSK filed the new drug application for uses in both CKD non-dialysis patients and in dialysis patients.
  • Ultimately, Jesduvroq was only granted approval for dialysis patients unlike what has been seen for other HIF-PH inhibitors – including daprodustat – globally.
  • Key initial findings from the Spherix study reveals that U.S. nephrologists are divided regarding their receptivity to the drug's recent approval.

Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical's Lupkynis and GSK's Benlysta, According to Spherix Global Insights

Retrieved on: 
Friday, January 20, 2023
Safety, Rituximab, Lupus nephritis, Hypertension, AstraZeneca, Skin, Novartis, Rheumatology, Secukinumab, Nephrology, FDA, Thumbay Hospital, Physician, Anemia, SGLT2, GSK plc, NASA RealWorld-InWorld Engineering Design Challenge, Roche, Proteinuria, EGFR, Patient, Clinical trial, Disease, Steroid, Research, Medical imaging, Pharmaceutical industry, Nursing, Belimumab, Aurinia, Anifrolumab, LN, Voclosporin

EXTON, Pa., Jan. 20, 2023 /PRNewswire/ -- With the approvals of GlaxoSmithKline's Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinia's Lupkynis (voclosporin) at the beginning of 2021, practitioners now have valuable new treatment options to battle this complex and serious condition.

Key Points: 
  • Spherix Global Insights has been a leader in tracking the lupus nephritis market for several years, covering physician perspectives, treatment patterns, and pipeline assessments.
  • Compared to the prior year (n=954 patients), use of Aurinia's novel calcineurin inhibitor expanded significantly, regardless of which specialty was managing the treatment regimen.
  • Use of Benlysta was relatively flat with rheumatology-managed patients being far more likely to be treated with the agent than nephrology-managed patients.
  • LN patients under nephrology management were three times as likely to be on an SGLT2 inhibitor compared to those under management of a rheumatologist.

Substantial Changes in Management of Patients with Chronic Kidney Disease as New Treatment Options Such as Bayer's Kerendia and SGLT2 Inhibitors Gain Traction in US and EU Markets

Retrieved on: 
Friday, January 20, 2023
RealTime, HIV disease progression rates, UK, Bayer, AstraZeneca, DKD, ARB, MRAS, MRA, PCP, Spironolactone, Kidney, CKD, Health, ACE, Nephrology, Eplerenone, Physician, SGLT2, NASA RealWorld-InWorld Engineering Design Challenge, Novo Nordisk, Patient, Prescription, Diabetic nephropathy, Cowra breakout, Research, Diabetes, Empagliflozin, Pharmaceutical industry, Finerenone, EU

EXTON, Pa., Jan. 20, 2023 /PRNewswire/ -- With SGLT2 inhibitors increasingly becoming the standard of care for diabetic and non-diabetic CKD patients, the broader CKD treatment has begun to change notably.

Key Points: 
  • Of note, while use of mineralocorticoid antagonists (MRAs) – including the newer option Kerendia (Bayer) – has increased over the past year, nephrologists indicate SGLT2 inhibitors remain their most likely first step for patients.
  • Since the approval of Kerendia in July 2021, the use of MRA products overall (inclusive of Kerendia, spironolactone, and eplerenone) in CKD non-dialysis patients has also grown substantially.
  • This research will build off the inaugural research in 2022 of 1,282 patients collected in collaboration with 263 European nephrologists.
  • Results of Spherix's second annual EU chart audit will publish later this spring with notable changes likely to appear.